DE3480928D1 - 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung. - Google Patents

5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung.

Info

Publication number
DE3480928D1
DE3480928D1 DE8484110168T DE3480928T DE3480928D1 DE 3480928 D1 DE3480928 D1 DE 3480928D1 DE 8484110168 T DE8484110168 T DE 8484110168T DE 3480928 T DE3480928 T DE 3480928T DE 3480928 D1 DE3480928 D1 DE 3480928D1
Authority
DE
Germany
Prior art keywords
substituted
pyrimidinone
nucleosides
pyrimidinone nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8484110168T
Other languages
English (en)
Inventor
Thomas J Bardos
Yung-Chi Cheng
Alan Curtis Schroeder
Ngale Efange Simon Mbua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Application granted granted Critical
Publication of DE3480928D1 publication Critical patent/DE3480928D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8484110168T 1984-08-20 1984-08-25 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung. Expired - Lifetime DE3480928D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/641,770 US4782142A (en) 1982-01-05 1984-08-20 Novel 5-substituted 2-pyrimidinone nucleosides and methods of use

Publications (1)

Publication Number Publication Date
DE3480928D1 true DE3480928D1 (de) 1990-02-08

Family

ID=24573773

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484110168T Expired - Lifetime DE3480928D1 (de) 1984-08-20 1984-08-25 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung.

Country Status (5)

Country Link
US (1) US4782142A (de)
EP (1) EP0175004B1 (de)
JP (1) JPS6153296A (de)
CA (1) CA1259611A (de)
DE (1) DE3480928D1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
JPH0217198A (ja) * 1988-07-05 1990-01-22 Japan Tobacco Inc ２’−デオキシ−β−シチジン誘導体およびその塩の製造法
JPH0217199A (ja) * 1988-07-05 1990-01-22 Japan Tobacco Inc ２’−デオキシ−β−アデノシンの製造方法
WO1990001324A1 (en) * 1988-08-10 1990-02-22 Stephen Leslie Sacks PRODUCTION OF RADIOIODINATED 1-β-D-ARABINOFURANOSYL)-5(E)-(2-IODOVINYL)URACIL, AND USES THEREOF, AND RELATED ANALOGUES INCORPORATING ALTERNATIVE HALOGEN RADIONUCLIDES, THE GENERAL RADIOHALOGENATION PRECURSORS, 1-(2,3,5-TRI-O-ACETYL-β-D-ARABINOFURANOSYL)-5(Z and E)-(2-TRIMETHYLSILYLVINYL)URACIL, PROCESSES FOR RADIOHA
JPH02160799A (ja) * 1988-12-13 1990-06-20 Yuki Gosei Kogyo Co Ltd ２′−デオキシ−β−アデノシンの製造法
US5214138A (en) * 1989-12-20 1993-05-25 Case Western Reserve University Imidazopyridinium compound and processes for isolating, identifying, and chemically synthesizing same
EP0586523A4 (en) * 1991-05-15 1995-11-29 Univ Yale Determination of prodrugs metabolizable by the liver and therapeutic use thereof
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
CN107540718B (zh) * 2017-10-26 2020-01-31 天津立博美华基因科技有限责任公司 1-（2-脱氧-β-D-呋喃核糖基）-5-碘-2-嘧啶酮的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561290A (en) * 1975-10-16 1980-02-20 Nyegaard & Co As Pyrimid - 2 - ones
DD134429A3 (de) * 1977-09-29 1979-02-28 Dieter Cech Verfahren zur herstellung von 1-(beta-d-ribofuranosyl)-5-fluorpyrimidin-2-on
GB2060604B (en) * 1979-10-03 1983-11-23 Univ Birmingham And Stichting E15-(2-halogenovinyl)-2'-deoxycytidines
JPS5687599A (en) * 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation

Also Published As

Publication number Publication date
EP0175004B1 (de) 1990-01-03
US4782142A (en) 1988-11-01
CA1259611A (en) 1989-09-19
EP0175004A2 (de) 1986-03-26
JPS6153296A (ja) 1986-03-17
EP0175004A3 (en) 1986-07-30

Similar Documents

Publication Publication Date Title
DE3582826D1 (de) Leitfaehige waermehaertbare zusammensetzungen und verfahren zu ihrer verwendung.
DE3878326T2 (de) Kunstlunge der membranart und verfahren zu ihrer verwendung.
DE69023417D1 (de) Anpassungsschaltung und Verfahren zu ihrer Verwendung.
DE69105793T2 (de) Löt-Polymer-Komposit-Paste und Verfahren zu ihrer Verwendung.
DE3577098D1 (de) Para-phenylensulfid-blockcopolymere, verfahren zu ihrer herstellung und ihre verwendung.
DE3577117D1 (de) Hydraulisch unterstuetztes turboladesystem und verfahren zu seinem betrieb.
DE68908980T2 (de) Legierung und Verfahren zu ihrer Verwendung.
DE3775581D1 (de) Bedampfungsanlage und verfahren zu deren verwendung.
DE3670483D1 (de) 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung.
DE3778148D1 (de) Zusammensetzungen mit discorhabdin, sowie verfahren zu deren verwendung.
DE3585780D1 (de) Analytische vorrichtung und verfahren zu ihrer verwendung.
DE3485876T2 (de) Zeolithischer katalysator und verfahren zu seiner verwendung.
DE3679028D1 (de) Benzylaminderivate, verfahren zu ihrer herstellung und ihre verwendung.
DE3481120D1 (de) 3,6-disubstituierte-1,8-naphthalimide, verfahren zu ihrer herstellung und ihre verwendung.
DE3480928D1 (de) 5-substituierte 2-pyrimidinon-nukleoside und verfahren zu ihrer verwendung.
DE3588039D1 (de) Azetidinonderivate und Verfahren zu ihrer Herstellung.
DE3481251D1 (de) Kontaktstift und verfahren zu seiner befestigung.
DE69022201D1 (de) Strahlenhärtbare Zusammensetzung und Verfahren zu deren Verwendung.
DE3878769D1 (de) Spachtelfaehige ablative beschichtungszusammensetzung und verfahren zu ihrer verwendung.
DE3578454D1 (de) Klinisches analysesystem und verfahren.
DE3581435D1 (de) Sonnenschutzmittel und verfahren zu dessen verwendung.
DE3575570D1 (de) Disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung.
DE3586324T2 (de) Tetrahydrophthalimidderivate, verfahren zu ihrer herstellung und ihre verwendung.
DE68905294D1 (de) Antimikrobische zusammensetzung und verfahren zu deren verwendung.
DE3682551D1 (de) Placenta-kollagenpraeparate, verfahren zu ihrer extraktion und ihre verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee